Amgen Inc. (NASDAQ:AMGN) Receives $354.60 Consensus PT from Brokerages
by Mitch Edgeman · The Markets DailyAmgen Inc. (NASDAQ:AMGN – Get Free Report) has been given an average rating of “Hold” by the thirty research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $354.60.
A number of equities research analysts have recently weighed in on AMGN shares. Argus raised their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. The Goldman Sachs Group boosted their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Guggenheim increased their price objective on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Citigroup lifted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, Morgan Stanley boosted their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 4th.
Get Our Latest Stock Analysis on AMGN
Amgen Stock Performance
Shares of AMGN opened at $347.94 on Wednesday. The company has a market capitalization of $187.56 billion, a PE ratio of 24.45, a PEG ratio of 3.45 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company’s 50 day moving average price is $363.65 and its 200 day moving average price is $332.36. Amgen has a 52 week low of $261.43 and a 52 week high of $391.29.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. The company’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts expect that Amgen will post 20.62 EPS for the current fiscal year.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.
Hedge Funds Weigh In On Amgen
Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp raised its holdings in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Capital World Investors lifted its position in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. Capital International Investors lifted its position in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.